Title: AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver
fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran
Version: 1 Date: 15 Apr 2023
Reviewer's report:
In the revised version, the authors answered my questions. The article is improved compared to
the initial version, but, obviously, the same major limits remain (lack of biopsy).
However, through the changes made, it is clearer that the study aimed to compare AST/ALT
ratio, APRI, and FIB-4 with FibroScan results. Also, the limits of the study are emphasized more
clearly in the discussion chapter.
Title: AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver
fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran
Version: 1 Date: 15 Apr 2023
Reviewer's report:
In the revised version, the authors answered my questions. The article is improved compared to
the initial version, but, obviously, the same major limits remain (lack of biopsy).
However, through the changes made, it is clearer that the study aimed to compare AST/ALT
ratio, APRI, and FIB-4 with FibroScan results. Also, the limits of the study are emphasized more
clearly in the discussion chapter.
Please review this paper.
user
Title: AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver
fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran
Version: 1 Date: 15 Apr 2023
Reviewer's report:
In the revised version, the authors answered my questions. The article is improved compared to
the initial version, but, obviously, the same major limits remain (lack of biopsy).
However, through the changes made, it is clearer that the study aimed to compare AST/ALT
ratio, APRI, and FIB-4 with FibroScan results. Also, the limits of the study are emphasized more
clearly in the discussion chapter.
assistant